Inhibrx Biosciences, Inc.INBXNASDAQ

Revenue (LTM)

$200000

-88.9% YoY

Net Income (LTM)

$1.7B

+799.2% YoY

Free Cash Flow

$-197M

Revenue CAGR (5Y)

-53.4%

Marginsdeclining

FCF($0.2B)

Now profitable

Metric	Dec 20	Dec 21	Dec 22	Dec 23	Dec 24
Revenue	13	7↓44.4%	2↓69.2%	2↓17.9%	0↓88.9%
Gross Profit	-61	4↑107.3%	-108↓2533.9%	1↑100.6%	-2↓442.4%
Operating Income	-67	-77↓13.5%	-129↓68.6%	-219↓69.8%	-331↓51.2%
Net Income	-76	-82↓8.1%	-145↓77.6%	-241↓66.2%	1,688↑799.2%
EBITDA	-64	-75↓18.1%	-126↓66.9%	-207↓64.3%	1,703↑924.1%
EPS Diluted	-2.99	-2.15↑28.1%	-3.62↓68.4%	-5.12↓41.4%	116.58↑2377.0%

Metric	Dec 20	Dec 21	Dec 22	Dec 23	Dec 24
Cash & Equivalents	129	131↑2.0%	274↑108.6%	278↑1.5%	153↓45.1%
Total Current Assets	132	139↑5.3%	280↑101.6%	295↑5.3%	160↓45.7%
Total Assets	144	150↑4.7%	291↑93.3%	308↑5.9%	181↓41.3%
Total Current Liabilities	31	22↓28.5%	28↑22.8%	56↑104.2%	41↓27.7%
Total Liabilities	68	98↑43.7%	233↑137.4%	264↑13.6%	47↓82.2%
Total Equity	75	52↓30.6%	58↑10.8%	44↓25.1%	134↑207.1%
Total Debt	37	72↑92.6%	207↑187.1%	210↑1.5%	8↓96.2%
Net Debt	-91	-59↑35.1%	-67↓12.9%	-68↓1.5%	-145↓113.3%

Metric	Dec 20	Dec 21	Dec 22	Dec 23	Dec 24
Operating Cash Flow	-48	-80↓67.5%	-115↓43.5%	-193↓67.7%	-194↓0.6%
Capital Expenditure	-1	-1↑36.7%	-1↑20.6%	-5↓569.5%	-3↑43.5%
Free Cash Flow	-49	-81↓64.6%	-116↓42.9%	-198↓70.6%	-197↑0.5%
Stock-Based Comp	5	15↑199.6%	20↑35.9%	25↑21.5%	59↑135.5%
Net Change in Cash	117	3↓97.7%	143↑5306.3%	4↓97.2%	-125↓3187.7%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance